Table 2.

Change scores on BII by treatment regimen according to baseline IPSS score

	Baseline IPSS (8–13)		Baseline IPSS (14–19)		Baseline IPSS (≥20)
	n	Mean change	n	Mean change	n	Mean change
Watchful waiting, mean (SD)	64	0.3 (1.7)	46	1.1 (2.0)1,2,3		–
Monotherapy, mean (SD)
AB	87	1.7 (1.9)	171	2.5 (2.4)1,4	118	2.8 (2.6)7,8
5ARI		–	34	2.1 (2.0)2,4,5	45	3.0 (2.5)7,9
HESr	269	1.2 (1.9)	256	2.0 (2.4)3,5	106	2.9 (3.1)8,9
Combination therapy, mean (SD)
AB + 5ARI		–	25	2.3 (2.5)6	58	3.7 (3.0)10
AB + HESr	32	2.2 (2.5)	84	2.9 (2.4)6	86	3.7 (2.6)10

Groups with <25 patients were excluded from the analysis due to small sample size and a high degree of variability in results

Numbers in superscript indicate the results of statistical testing

If there is no superscript number, then it was not possible to test for significance due to differences in the mean IPSS baseline score

IPSS International Prostate Symptom Score, BII Benign Prostatic Hyperplasia Impact Index, AB α- blockers, 5ARI 5α-reductase inhibitors, HESr hexanic extract of Serenoa repens

^1,2,3Statistically significant difference observed at p < 0.05 between groups with the same superscript number

^{4,5,6,7,8,9,10}No statistically significant differences observed between groups with the same superscript number